Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.

Imatinib mesylate (IM), a tyrosine kinase inhibitor, has shown efficacy for the treatment of chronic GVHD (cGVHD),1-3 with overall response rates of fibrotic skin symptoms evaluated in 2 open-label studies ranging from 50%1 to 79%.2 To assess the global long-term effectiveness of IM for sclerodermatous cGVHD, we performed a retrospective study on 39 patients with steroidresistant disease followed in 6 French hospitals (Table 1). At the onset of IM, all patients had sclerodermatous grade 2 (n 6, 15%) or grade 3 cGVHD (ie, deep sclerotic features, fasciitis, skin ulcers, or involvement of more than 50% of the body surface area; n 33, 85%) according to the National Institutes of Health (NIH) grading.4 Twenty-five patients (64%) had 1 or more organs involved apart from the skin, and bronchiolitis obliterans was observed in 18 patients (46%). Thirty-seven patients (95%) had received 2 or more treatment lines for cGVHD before IM treatment. IM was started after a mean delay of 29 28 months after the diagnosis of cGVHD. The response assessment was made by the physician according to his or her perception of the change in skin involvement evaluated as “improvement,” “stability,” or “worsening.” The physician’s perception of skin change was closely related to the NIH composite score that is correlated with overall mortality and was therefore used in this study.5 After an average treatment duration of 13 10 months, IM did not improve skin sclerosis in 70% of patients (stability 31%, worsening 39%). The overall improvement rate was 30%: 1 patient (2%) achieved complete remission (with 28 months of follow-up after IM start), 9 (23%) had improvement, and 2 (5%) had improvement and secondary worsening after initial remission (20 and 22 months after IM start, respectively). Systemic corticosteroids were tapered in 9 patients (23%) and discontinued in 7 patients (18%); however, among these 16 patients, 7 had no improvement of the skin symptoms, so corticosteroid tapering did not reflect the efficacy of IM, but rather the physician’s conviction that corticosteroids were ineffective. After a mean follow-up time of 18 12 months after Table 1. Patient characteristics, GVHD features, and response to imatinib (N 39)